Company: RGNT
Filing Date: 2025-05-05
Form Type: F-1/A
Source: 0001213900-25-039589
Chunk: 275

Company: REGENTIS BIOMATERIALS LTD.
Filing Date: 2025-05-05
Form: F-1/A
Chunk 275
---
9:- | COMMITMENTS AND CONTINGENCIES (Cont.) |

| 4. | In January 2024, the Company renewed its facility lease agreement until December 2024. The monthly                 
 rental obligations under non-cancellable leases are approximately $5.5 (including $3 for administrative expenses). |

As part of the agreement, the Company
has provided the landlord with a bank guarantee of approximately of $7 (NIS 27 thousand) which is valid until February 2025.

Future minimum lease payments under
non-cancelable operating leases as of December 31, 2024 are as follows:

| 2025 |     | USD | 66 |
|:-----|:----|:----|---:|
|      |     | $   | 66 |

The Company has elected to utilize
the practical expedient in ASC 842 for short-term leases (less than 12 months) whereby a lease liability and right of use asset will
not be recorded for short-term leases.

| 5. | In 2019, a disagreement has arisen between the Company and CSL Behring GmbH,                                                                                       
 or CSL, whether certain unshipped minimum purchase commitments for fibrinogen from 2018 to 2020 are to be paid by the Company pursuant                             
 to a Framework Supply Agreement dated March 8, 2016, or Framework Supply Agreement, by and between the Company and CSL, whereby CSL                                
 agreed to supply the Company with fibrinogen. On January 14, 2020, the Company received a termination letter, or CSL Termination                                   
 Letter. In the CSL Termination Letter, CSL demanded a total amount of $820, claiming it was owed the minimum purchase commitment                                   
 amounts under the Framework Supply Agreement not paid by the Company in 2018 and 2019. In a subsequent correspondence, CSL additionally                            
 demanded interest and damages for lost profit, with an aggregate demand amount of $1,476. The Company has disputed CSL’s payment                                   
 demand and contends that CSL’s demands are baseless under the Framework Supply Agreement, as the minimum purchase commitment                                       
 under the Framework Supply Agreement is conditional upon first obtaining approval of the FDA and the European Medicines Evaluation                                 
 Agency, or EMEA, and other quality and clinical milestones, none of which has occurred. Notwithstanding, CSL claimed to have obtained                              
 a valid German court order in its favor and to endeavor to seek for its enforcement in Israel. Company’s position is that CSL’s                                    
 claim for the payment